|
|
|
front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |review |
 |
DNA microarrays: Associations with
tumor histology, patient outcome, and treatment response
Tests of differential expression
T-test
SNR
Oncogenic events are often
heterogeneous
Her2/neu amplification in 20% breast
cancer
Activating Ras mutations in 25%
melanoma
E2A-PBX1 translocation in 5-10%
leukemia
High-level amplifications and
promoter-driver type translocations should lead to over-expression
Tests of differential expression
T-test
SNR
Oncogenic events are often
heterogeneous
Her2/neu amplification in 20% breast
cancer
Activating Ras mutations in 25%
melanoma
E2A-PBX1 translocation in 5-10%
leukemia
High-level amplifications and
promoter-driver type translocations should lead to over-expression
|